Central sympatholytic drugs

Journal of Clinical Hypertension

Volumn 13, Issue 9, 2011, Pages 658-661

  Vongpatanasin, Wanpen ^a   Kario, Kazuomi ^b   Atlas, Steven A ^c   Victor, Ronald G ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; GUANABENZ; GUANFACINE; METHYLDOPA; MOXONIDINE; NORADRENALIN; RESERPINE; RILMENIDINE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ANXIETY DISORDER; BEDTIME DOSAGE; BLOOD PRESSURE REGULATION; BRAIN STEM; COOMBS POSITIVE HEMOLYTIC ANEMIA; DEPRESSION; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FATIGUE; FEVER; GYNECOMASTIA; HEADACHE; HEART PALPITATION; HEMOLYTIC ANEMIA; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; LIVER DYSFUNCTION; NOSE CONGESTION; PANCREATITIS; PARKINSONISM; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; REBOUND; REVIEW; SEDATION; SIDE EFFECT; SYMPATHETIC NERVE; TERATOGENICITY; TREATMENT REFUSAL; TREMOR; XEROSTOMIA;

ANTIHYPERTENSIVE AGENTS; FATIGUE; HUMANS; HYPERTENSION; RECEPTORS, ADRENERGIC, ALPHA-2; SYMPATHETIC NERVOUS SYSTEM; SYMPATHOLYTICS; TREATMENT OUTCOME;

EID: 80052538033     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00509.x     Document Type: Review

References (36)

1. DeQuattro V, Li D. Sympatholytic therapy in primary hypertension: a user friendly role for the future. J Hum Hypertens. 2002;16(Suppl 1):S118-S123.
2. Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs. 2006;66:477-496.
3. Wallin BG, Frisk-Holmberg M. The antihypertensive mechanism of clonidine in man. Evidence against a generalized reduction of sympathetic activity. Hypertension. 1981;3:340-346.
4. Miyajima E, Shigemasa T, Endo T, et al. Guanabenz combination therapy inhibits sympathetic nerve activity and regresses left ventricular hypertrophy. Cardiovasc Drugs Ther. 2000;14:61-66.
5. Szabo B. Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol Ther. 2002;93:1-35.
6. Anavekar SN, Howes LG, Jarrott B, et al. Pharmacokinetics and antihypertensive effects of low dose clonidine during chronic therapy. J Clin Pharmacol. 1989;29:321-326.
7. Louis WJ, McNeil JJ, Anavekar SN, et al. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents. J Cardiovasc Pharmacol. 1987;10(Suppl 12):S100-S103.
8. Lund-Johansen P. Hemodynamic changes at rest and during exercise in long-term clonidine therapy of essential hypertension. Acta Med Scand. 1974;195:111-115.
9. Farsang C, Varga K, Vajda L, et al. Effects of clonidine and guanfacine in essential hypertension. Clin Pharmacol Ther. 1984;36:588-594.
10. Weber MA, Drayer JI, Laragh JH. The effects of clonidine and propranolol, separately and in combination, on blood pressure and plasma renin activity in essential hypertension. J Clin Pharmacol. 1978;18:233-240.
11. Lowenthal DT, Matzek KM, MacGregor TR. Clinical pharmacokinetics of clonidine. Clin Pharmacokinet. 1988;14:287-310.
12. MacGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther. 1985;38:278-284.
13. One year efficacy and tolerability of clonidine administered by the transdermal route in patients with mild to moderate essential hypertension - a multicentre open label study. The Antihypertensive Patch Italian Study (APIS) Investigators. Clin Auton Res. 1993;3:379-383.
14. Ito MK, O'Connor DT. Skin pretreatment and the use of transdermal clonidine. Am J Med. 1991;91:42S-49S.
15. Weber MA. Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents. J Cardiovasc Pharmacol. 1980;2(Suppl 1):S73-S89.
16. Karachalios GN, Charalabopoulos A, Papalimneou V, et al. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract. 2005;59:562-570.
17. Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1986;31:301-336.
18. Seedat YK. Clonidine and guanfacine--comparison of their effects on haemodynamics in hypertension. S Afr Med J. 1985;67:557-559.
19. Magometschnigg D, Hitzenberger G, Bonelli J. Haemodynamic effects of guanfacine. Br J Clin Pharmacol. 1980;10(Suppl 1):125S-131S.
20. Schafer N, Rauh J, Rosenthal J. Haemodynamics in hypertensive patients before and during guanfacine treatment. Br J Clin Pharmacol. 1980;10(Suppl 1):133S-135S.
21. Wilson MF, Haring O, Lewin A, et al. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. Am J Cardiol. 1986;57:43E-49E.
22. Kisicki JC, Fiske K, Lyne A. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther. 2007;29:1967-1979.
23. Bobik A, Jennings G, Jackman G, et al. Evidence for a predominantly central hypotensive effect of alpha-methyldopa in humans. Hypertension. 1986;8:16-23.
24. Myhre E, Rugstad HE, Hansen T. Clinical pharmacokinetics of methyldopa. Clin Pharmacokinet. 1982;7:221-233.
25. Myhre E, Stenbaek O, Rugstad HE, et al. Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients. Scand J Urol Nephrol. 1982;16:257-263.
26. Mohammed S, Fasola AF, Privitera PJ, et al. Effect of methyldopa on plasma renin activity in man. Circ Res. 1969;25:543-548.
27. Montan S, Anandakumar C, Arulkumaran S, et al. Effects of methyldopa on uteroplacental and fetal hemodynamics in pregnancy-induced hypertension. Am J Obstet Gynecol. 1993;168:152-156.
28. Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007;9:399-405.
29. Lasseter KC, Shapse D, Pascucci VL, Chiang ST. Pharmacokinetics of guanabenz in patients with impaired liver function. J Cardiovasc Pharmacol. 1984;6(Suppl 5):S766-S770.
30. Hashimoto J, Chonan K, Aoki Y, et al. Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension: evaluation using home-based blood pressure measurements. J Hypertens. 2003;21:805-811.
31. Holmes B, Brogden RN, Heel RC, et al. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1983;26:212-229.
32. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-988.
33. Robertson D, Hollister AS, Biaggioni I, et al. The diagnosis and treatment of baroreflex failure. N Engl J Med. 1993;329:1449-1455.
34. Shamon SD, Perez MI. Blood pressure lowering efficacy of reserpine for primary hypertension. Cochrane Database Syst Rev. 2009:CD007655.
35. Kostis JB, Berge KG, Davis BR, et al. Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). Am J Hypertens. 1995;8:1147-1153.
36. Pernow J, Thoren P, Millberg BI, et al. Renal sympathetic nerve activation in relation to reserpine-induced depletion of neuropeptide Y in the kidney of the rat. Acta Physiol Scand. 1988;134:53-59.